1,1-Dioxo-5,6-dihydro-[4,1,2]oxathiazines, a novel class of 11ß-HSD1 inhibitors for the treatment of diabetes
Authors:
- Christian K. EngelCEChristian K. Engel
- Géraldine FarjotGFGéraldine Farjot
- Stefan GüssregenSGStefan Güssregen
- Torsten HaackTHTorsten Haack
- Georg TschankGTGeorg Tschank
- Kurt RitterKRKurt Ritter
- 1 August 2013
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 23 (16) , 4685-4691
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- The effects of glucocorticoids on adipose tissue lipid metabolismMetabolism, 2011
- Small Molecule 11β- Hydroxysteroid Dehydrogenase Type 1 InhibitorsCurrent Topics in Medicinal Chemistry, 2011
- 11 β ‐Hydroxysteroid dehydrogenase type 1 inhibition in type 2 diabetes mellitusDiabetes, Obesity and Metabolism, 2010
- 11β-Hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetesExpert Opinion on Investigational Drugs, 2010
- Obesity and corticosteroids: 11β-Hydroxysteroid type 1 as a cause and therapeutic target in metabolic diseaseMolecular and Cellular Endocrinology, 2010
- 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors as Promising Therapeutic Drugs for Diabetes: Status and DevelopmentCurrent Medicinal Chemistry, 2010
- 11β-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patentsExpert Opinion on Therapeutic Patents, 2009
- Inhibitors of 11β-HSD1: A Potential Treatment for the Metabolic SyndromeCurrent Topics in Medicinal Chemistry, 2008
- Blockade of Glucocorticoid Excess at the Tissue Level: Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 as a Therapy for Type 2 DiabetesJournal of Medicinal Chemistry, 2008
- 11β-Hydroxysteroid Dehydrogenase Type 1: A Tissue-Specific Regulator of Glucocorticoid ResponseEndocrine Reviews, 2004